Search
Galmed Pharmaceuticals Ltd
GLMDAdd to Watchlist
3.625USD
+0.125+3.57%
Close 09-09 16:00（ET）
29.94MMarket Cap
LossP/E TTM
GLMD Analyst Recommendation Trends
In the current month, GLMD has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. GLMD average Analyst price target in the last month is 0.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
GLMD Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, GLMD EPS is projected to reach -3.060 in FY2026Q3, following reported EPS of -2.860 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-4.08
-3.04
-3.12
-3.06
-3.17
Actual
-0.80
-2.32
-2.86
--
--
Surprise
+80.37%
+23.74%
+8.34%
--
--
FAQs
How have Galmed Pharmaceuticals LtdGLMD's recent earnings per share performed?
The market expectation was USD -2.86, while Galmed Pharmaceuticals LtdGLMD's earnings per share (EPS) for the previous quarter was USD -2.32. EPS for the next quarter is expected at USD -3.06.
What is the analyst rating for Galmed Pharmaceuticals Ltd?
Based on the ratings of Galmed Pharmaceuticals Ltd's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.